| Literature DB >> 22316093 |
Josef Thingnes1, Timothy J Lavelle, Arne B Gjuvsland, Stig W Omholt, Eivind Hovig.
Abstract
BACKGROUND: Expression of the two transcription factors microphthalmia-associated transcription factor (MITF) and signal transducer and activator of transcription 3 (STAT3) are tightly connected to cell proliferation and survival, and are important for melanocyte development. The co-regulation of MITF and STAT3 via their binding to a common inhibitor Protein Inhibitor of Activated STAT3 (PIAS3) is intriguing. A better quantitative understanding of this regulation is likely to be important for elucidation of the melanocyte biology.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22316093 PMCID: PMC3341200 DOI: 10.1186/1752-0509-6-11
Source DB: PubMed Journal: BMC Syst Biol ISSN: 1752-0509
Figure 1Overview of the modelled network. The two transcription factors MITF and STAT3 are phosphorylated by the MAPK-pathway and the JAK-STAT-pathway, respectively. PIAS3 inhibits their activity as transcription factors by binding and forming inactive complexes. The abundance of one transcription factor can sequester PIAS3 to depletion, and eliminate the inhibition of the other transcription factor.
Figure 2Graphical representation of the model. The graphs are represented in Systems Biology Graphical Notation [51] as implemented in CellDesigner [50] version 4.2. A: The diagram shows the different states of each protein (rounded rectangles) and the possible state transitions (arrows). Catalysed transitions are depicted as lines from the catalyst to a circle at the state transition arrow. The model has two input nodes: ERK and JAK (white nodes). ERK is phosphorylating RSK1 (grey nodes). ERK and RSK1 are phosphorylating MITF (red nodes) at S73 (blue lines) and S409 (pink lines), respectively. MITF in different phosphorylation states combines (red lines) with PIAS3 (yellow nodes) forming complexes (orange grouping nodes). On the other side, JAK phosphorylates STAT3 (blue nodes), which is going into complex with PIAS3 when activated (green grouping node). The output nodes of the model are all the free MITF states and the phosphorylated STAT3. Communication between the ERK-RSK-MITF pathway and the JAK-STAT pathway via the competitive binding to free PIAS3 is the topic of this work. B: Production and degradation. The amounts of phosphorylated ERK and JAK are represented by constants. The total amount of RSK1 is constant while the phosphorylation state is dynamically determined. The amounts of MITF, PIAS3 and STAT3 are dynamically determined by the production and degradation of the proteins. The broken arrows from the genes (yellow rectangles) to the proteins represent production, while arrows from the proteins to the degradation node (red filled empty set symbol) represent degradation. C: Ubiquitination of MITF. All S73 phosphorylated MITF can be ubiquitin tagged, in which case it will eventually be degraded. The ubiquitination is catalysed by phosphorylated ERK.
List of core parameters
| No | Parameter | Value | Description |
|---|---|---|---|
| 1 | 0.00015 | MITF phosphorylation on S73, ERK dependent (Mol-1min-1) | |
| 2 | 0.03 | MITF de-phosphorylation on S73 (min-1) | |
| 3 | 0.025 | MITF auto-phosphorylation on S73 (min-1) | |
| 4 | 0.0001 | MITF phosphorylation on S409 (Mol-1min-1) | |
| 5 | 0.04 | MITF de-phosphorylation on S409 (min-1) | |
| 6 | 0.01 | MITF/PIAS3 association (Mol-1min-1) | |
| 7 | 1 | MITF/PIAS3 dissociation (min-1) | |
| 8 | 0.03 | MITFp79/PIAS3 association (Mol-1min-1) | |
| 9 | 0.5 | MITFp79/PIAS3 dissociation (min-1) | |
| 10 | 0.0001 | MITFp409/PIAS3 association (Mol-1min-1) | |
| 11 | 1 | MITFp409/PIAS3 dissociation (min-1) | |
| 12 | 0.01 | MITFpp/PIAS3 association (Mol-1min-1) | |
| 13 | 1 | MITFpp/PIAS3 dissociation (min-1) | |
| 14 | 0.0002 | STAT3 phosphorylation (Mol-1min-1) | |
| 15 | 0.04 | STAT3 de-phosphorylation (min-1) | |
| 16 | 0.005 | STAT3p/PIAS3 association (Mol-1min-1) | |
| 17 | 0.2 | STAT3p/PIAS3 dissociation (min-1) | |
| 18 | 1 | MITF production (Mol min-1) | |
| 19 | 0.0012 | MITF degradation (min-1) | |
| 20 | 0.02 | MITFp73 degradation (min-1) | |
| 21 | 0.01 | MITFp409 degradation (min-1) | |
| 22 | 0.262 | PIAS3 production (Mol min-1) | |
| 23 | 0.008 | PIAS3 degradation (min-1) | |
| 24 | 0.211 | STAT3 production (Mol min-1) | |
| 25 | 0.002 | STAT3 degradation (min-1) | |
| 26 | 0.0004 | RSK1 phosphorylation (Mol-1min-1) | |
| 27 | 0.04 | RSK1 de-phosphorylation (min-1) | |
| 28 | 10 | ERKp concentration (Mol) | |
| 29 | 10 | JAKp concentration (Mol) | |
| 30 | 0.0001 | Ubiquitination (Mol-1min-1) | |
The parameter names follow a naming convention. The rate constants for phosphorylation events is a k with a subscript starting with a protein specification (R:RSK1, M:MITF or S:STAT3), followed by a specification of a phosphorylation site (p73, p409 for MITF and p for STAT3) and finalized with a ' + ' for phosphorylation rate constants and ' - ' for de-phosphorylation rate constants. The association and dissociation rate constants is a k with a subscript starting with a protein specification followed by a phosphorylation state specification, and finalized with ' ass ' or ' diss ' respectively. The name of the parameters denoting the production or degradation rates start with a p or a γ respectively, and ends with a specification of the protein (and eventually phosphor state). The two constants ERKp and JAKp, represent the amounts of phosphorylated ERK and JAK, respectively. These are altered to emulate signalling through the respective pathways. 'k' is the ubiquitination rate constant.
An overview of the biological experiments
| Description | Reference | |
|---|---|---|
| 1. | Temporal development of ERK and RSK1 kinase activity | [ |
| 2. | Distribution between MITF phosphorylation before stimulation | [ |
| 3. | Temporal development of MITF phosphorylation states after stimulation | [ |
| 4. | Temporal development of MITF degradation | [ |
| 5. | MITF activity in response to PIAS3 transfection | [ |
| 6. | Amount of MITF-PIAS3 complex in response to activation | [ |
| 7. | Amount of MITF-PIAS3 complex in response to activation with transfected MITF and PIAS3 | [ |
| 8. | MITF activity in response to transfection of constitutively active RSK1 | [ |
| 9. | MITF activity in response to PIAS3 | [ |
| 10. | MITF activity in response to transfection of PIAS3 and active RSK1 | [ |
| 11. | Activity of a MITF-S409A mutant in response to PIAS3 | [ |
| 12. | Activity of a MITF-S409A mutant in response to transfection of PIAS3 and active RSK1 | [ |
| 13. | Activity of MITF in response to transfection of PIAS3 | [ |
| 14. | Activity of MITF-S73D mutant in response to transfection of PIAS3 | [ |
| 15. | Activity of MITF-S409D mutant in response to transfection of PIAS3 | [ |
| 16. | Activity of MITF-S73/409D mutant in response to transfection of PIAS3 | [ |
| 17. | MITF-PIAS3 association in response to activation | [ |
| 18. | S409A mutated MITF-PIAS3 association in response to activation | [ |
| 19. | STAT3 activity in response to activation | [ |
| 20. | STAT3 activity in response to activation with transfected PIAS3 | [ |
| 21. | STAT3 activity in response to activation with transfected PIAS3 and small amount of MITF | [ |
| 22. | STAT3 activity in response to activation with transfected PIAS3 and large amount of MITF | [ |
| 23. | STAT3 activity in response to activation with transfected PIAS3 and small amount of S-409A mutated MITF | [ |
| 24. | STAT3 activity in response to activation with transfected PIAS3 and large amount of S409A mutated MITF | [ |
| 25. | MITF activity in response to transfection of Y705F mutated STAT3 and STAT3-C | [ |
| 26. | MITF and STAT3 activity in response to activation compared between wild type and mutated MITF (unable to bind PIAS3) | [ |
| 27. | STAT3 activity in response to transfection of MITF or S409D MITF mutation | [ |
| 28. | MITF activity in response to transfection of STAT3-C | [ |
The numbers assigned to each experiment in the table is used to identify the experiment throughout this paper. For each experiment the reference and the figure number within the reference are provided.
Figure 3Parameter sensitivity for all experiments. Sensitivity for all experiments to perturbations in each parameter after permutations to remove clearly insensitive parameters (no parameters passed the permutation threshold for experiment #26) is shown. Colour indicates the normalized sensitivity measure Each experiment is insensitive to perturbations in the dark blue parameters, while highly sensitive to the brown parameters.
Figure 4Simulations and lab results experiment #25. A: Reprint of figure 4B in [22] (License agreement number 2838800627526): NIH 3T3 cells were co-transfected with the luciferase reporter under the control of the mMCP6 promoter, MITF, PIAS3, and STAT3 mutants (STAT3-C and Y705F-STAT3). B: Simulation of the same experiment (Experiment 25 in Table 2). The white bars in the reprint and the blue bars in the simulation results represent the MITF activity in cells transfected with only STAT3, the grey bars in the reprint and the green bars in the simulation results represent the MITF activity in cells transfected with STAT3 and MITF, and the black bars in the reprint and the red bars in the simulation results represents the MITF activity in cells transfected with STAT3, MITF and PIAS3.
Figure 5Simulations and lab results experiment #7. A: Reprint of Figure 2B in [20] (License agreement number 2773700432120): Kinetics of MITF and PIAS3 association in TPA-activated BL6-B16 cells. Coimmunoprecipitation (IP) of PIAS3 with MITF at defined time points in TPA-activated BL6-B16 cells. The cells were transfected with pcDNA-MITF and pcDNAPIAS3. The blots were probed with anti-MITF antibodies and then reprobed with anti-PIAS3 antibody. Phosphorylation states represented by the upper band are unknown, the lower band is anticipated to represent un-phosphorylated MITF. B: Simulation of the same experiment (experiment #7 in Table 2). The temporal development of the amount of MITF-PIAS3 complex is plotted for all phosphorylation states of MITF, as well as for the sum of the phosphorylated states (PIAS3-MITFpAll).
Figure 6Simulations and lab results experiments #19 - #24. A: Reprint of Figure 3B in [22] (License agreement number 2838800627526): NIH 3T3 cells were co-transfected with STAT3, PIAS3 and with different doses of MITF (wild type [WT] or S409A [MUT] (capital letter denoting the greater dose)). Cells were triggered with IL-6/IL-6R for 6 h. B: Simulation of the same experiment (experiments 19-24 in Table 2).
Figure 7Simulations and lab results experiment #26. A: Reprint of figure 6D and E from [22] (License agreement number 2838800627526): Quantitative reverse transcription-PCR analysis of MITF target genes (c-Kit and TPH) and STAT3 target genes (c-Myc and VEGF) from BMMC activated for 0.5 or 4h with SCF derived from either wild-type or MITFdi/di mice. (B and C) Simulations of the same experiment (experiment #26 in Table 2). Note that the di/di mutation blocks the activation of both MITF and STAT3 in the reprinted lab result while in the simulation STAT3 activity is not affected.